Legal Opinion
Merrell Dow Pharmaceuticals Inc. v. Oxendine
District of Columbia Court of Appeals
Decided November 9, 1994No. 92-CV-1129PublishedCited by 16 opinions
1Opinion of the Court
STEADMAN, Associate Judge:
The fourth appeal in this extended litigation raises two issues: first, whether the trial court properly ruled that neither the Federal Food, Drug, and Cosmetic Act (“FDCA”), 21 U.S.C. §§ 301-393 (1988 & Supp. V 1994), nor approval of Bendectin by the Food and Drug Administration (“FDA”) preempts state1 tort law; and second, whether the trial court properly refused to reconsider the jury verdict in the light of post-trial developments. We hold that the trial court correctly decided the preemption issue and correctly determined that Merrell Dow must meet a rigorous…
2Cases cited42 opinions
- Daubert v. Merrell Dow Pharmaceuticals, Inc.Supreme Court of the United States · 1993
- Rice v. Santa Fe Elevator Corp.Supreme Court of the United States · 1947
- Cipollone v. Liggett Group, Inc.Supreme Court of the United States · 1992
- Hillsborough County v. Automated Medical Laboratories, Inc.Supreme Court of the United States · 1985
- Silkwood v. Kerr-McGee Corp.Supreme Court of the United States · 1984
37 more not listed; retrieve them via the Exa API.
3Cited by16 opinions
- Merrell Dow Pharmaceuticals, Inc. v. HavnerTexas Supreme Court · 1997
- Brenda Griffin Toole, Plaintiff-Appellee-Cross-Appellant v. Baxter Healthcare Corporation, Defendant-Appellant-Cross-AppelleeCourt of Appeals for the Eleventh Circuit · 2000
- American Continental Insurance Co. v. PooyaDistrict of Columbia Court of Appeals · 1995
- Diamen v. United StatesDistrict of Columbia Court of Appeals · 1999
- In Re Estate of CouseDistrict of Columbia Court of Appeals · 2004
11 more not listed; retrieve them via the Exa API.